Determinants of Hearing Recovery in Multidrug-Resistant Tuberculosis Patients with Ototoxic Hearing Loss: A Prospective Observational Cohort Study in Kinshasa, Democratic Republic of the Congo.
DOI:
https://doi.org/10.47941/ijhmnp.3313Keywords:
Multidrug-Resistant Tuberculosis, Determinants, Hearing RecoveryAbstract
Purpose. The ototoxic hearing loss (HL) during the treatment of multidrug-resistant tuberculosis (MDR-TB) remains a public health challenge, especially in resource-limited settings such as the Democratic Republic of the Congo (DRC). This study seeks to identify the risk factors associated with the hearing recovery (HR) in MDR-TB patients in order to implement effective preventive strategies.
Methodology. This prospective observational and analytic study included patients with MDR-TB. It was carried out in Kinshasa (Democratic Republic of the Congo) between February 15, 2020 and February 14, 2021. Sociodemographic, clinical, biological, therapeutic, and audiometric data were obtained and analyzed using SPSS for Windows software version 21. The hearing recovery (HR) was considered good if the final hearing loss (HL) was < 45 dB and poor if it was ≥ 45 dB. Pearson’s Chi-square or Fisher’s exact tests, as appropriate, were used to compare proportions. A multivariate logistic regression model was used to identify independent determinants of the HR. Odds ratios were provided with their 95% confidence intervals (Cis). Statistical significance was set at p < 0.05.
Findings. Of the 310 patients were examined (mean age 34.5 ± 14 years, men 64.8%), 245 patients (79%) received only an aminoglycosides-based regimen, 31 (10%) received only bedaquiline (BDQ), and 34 (11%) received aminoglycosides (AG) followed by BDQ. Twenty-eight patients (9%) had a positive HIV serology, two-thirds were anemic (67.4%) and one-third (32.9%) had hypoalbuminemia. According to the final HL at the three months of treatment, 89 patients (28.7%) had experienced a good HR. Age under 40 years (p =0.002), the BDQ regimen (p < 0.001), normal hearing and mild HL (p < 0.001), and the type A and B audiometric curve (p < 0.001) were significantly associated with a favorable HR. Whereas, the presence of tinnitus (p = 0.031), hypoacusis (p < 0.001), hypoalbuminemia (p = 0.046), anemia (p = 0.044), and chronic renal failure (p = 0.040) were associated with a poor HR. In the multivariable logistic regression analysis, a moderate HL (OR 3.71; 95% CI [1.71 – 8.28]; p =0.001) and a type B audiometric curve (OR 2.27; 95% CI [1.72 -7.8]; p =0.001) emerged as the main determinants of a good HR.
Unique contributor to theory, policy and practice: The hearing recovery in MDR-TB patients is poor during the treatment. This requires a regular audiometric monitoring to detect the early hearing loss. To reduce the risk of an ototoxic hearing impairment, it is recommended to prioritize the use of bedaquiline and to address adverse prognostic factors such as anemia, hypoalbuminemia, and impaired renal function. Hence, the need for large prospective and interventional studies to confirm these results.
Downloads
References
1. Global tuberculosis report 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO.
https://iris.who.int/bitstream/handle/10665/379339/9789240101531eng.pdf?sequence=1
2. Prasad K, Borre ED, Dillard LK, Ayer A, Der C, Bainbridge KE, et al.. Priorities for hearing loss prevention and estimates of global cause-specific burdens of hearing loss: a systematic rapid review. Lancet Glob Health. 2024; 12(2):e217-e225.
3. Kashongwe, I., Mbulula, L., Mawete, F., Anshambi, N., Maingowa, N., Kaswa, M., et al. Implementing a Short Regimen for Multidrug-Resistant Tuberculosis in Kinshasa, Democratic Republic of Congo: A Cohort Study 2014-2017. J. Tuberc. Res. 2020; 8, 111-126. doi: 10.4236/jtr.2020.83010.
4. Kashongwe, I.M., Anshambi, N., Maingowa, N., Aloni, M., Kaswa, M., Ntumba Kayembe, J.M., et al. Use of Bedaquiline as Replacement for Aminoglycosides in the Shorter Regimen for Multidrug-Resistant Tuberculosis Patients with Hearing Loss: A Report of 39 Cases in Kinshasa, Democratic Republic of the Congo. Journal of Pulmonary & Respiratory Medicine. 2020; 10, 1-6.
5. Mpwate, M. A., Mesia, G. K., Mbambu, E. M., Lema, G. M., Matanda, C. N., Mupepe, D. M., et al. Prevalence and Determinants of Hearing Loss in Multidrug-Resistant Tuberculosis Patients: A Prospective Observational Cohort Study in Kinshasa, Democratic Republic of the Congo. International Journal of Health, Medicine and Nursing Practice 2025, 8 (3): 30–43. https://doi.org/10.47941/ijhmnp.3238
6. Trébucq A, Schwoebel V, Kashongwe Z, Bakayoko A, Kuaban C, Noeske J, et al. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries. Int J Tuberc Lung Dis. 2018; 22(1):17-25.
7. Fassad MR, Desouky LM, Asal S, Abdalla EM. Screening for the mitochondrial A1555G mutation among Egyptian patients with non-syndromic, sensorineural hearing loss. Int J Mol Epidemiol Genet. 2014; 5(4):200-4. PMID: 25755848; PMCID: PMC4348701.
8. Mpwate AM, Matanda NR, Mupepe MD, Mafuta ME. Surdités neurosensorielles: à propos de 97 observations aux Cliniques Universitaires de Kinshasa. Ann. Afr. Med. 2012; 6(1): 1232-1241.
9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252
10. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120(16):1640-5.
11. Babor T.F, Higgins-Biddle J.C, Saunders J.B.,Monteiro M.G. AUDIT.-The Alcohol Use Disorders Identification Test : Guidelines for Use in Primary Care (Second Edidtion) (2001). https://www.who.int/publications/i/item/WHO-MSD-MSB-01.6a
12. Orth SR, Stockmann A, Conradt C, Ritz E, Ferro M, Kreusser W, et al. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 1998, 54(3): 926 -31.
13. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity (2011). https://www.who.int/publications/i/item/WHO-NMH-NHD-MNM-11.1
14. Oster HS, Dolev Y, Kehat O, Weis-Meilik A, Mittelman M. Serum Hypoalbuminemia Is a Long-Term Prognostic Marker in Medical Hospitalized Patients, Irrespective of the Underlying Disease. J Clin Med. 2022; 11(5):1207. doi: 10.3390/jcm11051207. PMID: 35268297; PMCID: PMC8911288
15. KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney international supplements. 2013, 3(1): 1 – 160.
16. Vasconcelos KA, Frota SMMC, Ruffino-Netto A, Kritski AL. The importance of audiometric monitoring in patients with multidrug-resistant tuberculosis. Rev Soc Bras Med Trop. 2017; 50(5):646-651.
17. Van Altena R, Dijkstra JA, van der Meer ME, Borjas Howard JF, Kosterink JG, van Soolingen D, et al. Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother. 2017; 61(3):e01400-16. doi: 10.1128/AAC.01400-16
18. Modongo C, Sobota RS, Kesenogile B, Ncube R, Sirugo G, Williams SM, et al. Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss. BMC Infect Dis. 2014; 14:542.
19. Hong H, Dowdy DW, Dooley KE, Francis HW, Budhathoki C, Han HR et al. Aminoglycoside-induced Hearing Loss Among Patients Being Treated for Drug-resistant Tuberculosis in South Africa: A Prediction Model. Clin Infect Dis. 2020; 14; 70(5):917-924. doi: 10.1093/cid/ciz289.
20. Sogebi OA, Adefuye BO, Adebola SO, Oladeji SM, Adedeji TO. Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy. Auris Nasus Larynx. 2017; 44(4):404-410. doi: 10.1016/j.anl.2016.10.005.
21. De Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis. 2002; 6(7):622-7. PMID: 12102302.
22. Harrison RV, Evans EF. Reverse correlation study of cochlear filtering in normal and pathological guinea pig ears. Hear Res. 1982; 6(3):303-14. doi: 10.1016/0378-5955(82)90062-4
23. Evans EF, Harrison RV. Proceedings: Correlation between cochlear outer hair cell damage and deterioration of cochlear nerve tuning properties in the guinea-pig. J Physiol. 1976 ;256(1):43P-44P
24. Kujawa SG, Liberman MC. Adding insult to injury: cochlear nerve degeneration after "temporary" noise-induced hearing loss. J Neurosci. 2009; 29(45):14077-85. doi: 10.1523/JNEUROSCI.2845-09.2009.
25. Duggal P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear Nose Throat Disord. 2007; 7:5. doi: 10.1186/1472-6815-7-5
26. Javadi MR, Abtahi B, Gholami K, Safari Moghadam B, Tabarsi P, Salamzadeh J. The Incidence of Amikacin Ototoxicity in Multidrug-ResistantTuberculosis Patients. Iran J Pharm Res. 2011 Fall; 10(4):905-11.
27. Ahmed RM, Hannigan IP, MacDougall HG, Chan RC, Halmagyi GM. Gentamicin ototoxicity: a 23-year selected case series of 103 patients. Med J Aust. 2012; 196(11):701-4. doi: 10.5694/mja11.10850.
28. Rybak LP, Whitworth CA. Ototoxicity: therapeutic opportunities. Drug Discov.Today. 2005; 10:1313-1321.
29. Rizzi MD, Hirose K. Aminoglycoside ototoxicity. Curr.Opin.Otolaryngol.Head Neck Surg. 2007; 15:352-357.
30. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics 2004; 114:e111-118.
31. Richardson GP, Russell IJ. Cochlear cultures as a model system for studying aminoglycoside induced ototoxicity. Hear.Res. 1991; 53:293-311.
32. Hashino E, Shero M. Endocytosis of aminoglycoside antibiotics in sensory hair cells. Brain Res. 1995; 704:135-140.
33. Richardson GP, Forge A, Kros CJ, Fleming J, Brown SD, Steel KP. Myosin VIIA is required for aminoglycoside accumulation in cochlear hair cells. J.Neurosci. 1997; 17:9506-9519.
34. Richardson GP, Forge A, Kros CJ, Marcotti W, Becker D, Williams DS, et al. A missense mutation in myosin VIIA prevents aminoglycoside accumulation in early postnatal cochlear hair cells. Ann NY Acad Sci 1999; 884:110-124. PMID: 10842588.
35. Marcotti W, van Netten SM, Kros CJ. The aminoglycoside antibiotic dihydrostreptomycin rapidly enters mouse outer hair cells through the mechano-electrical transducer channels. J.Physiol. 2005; 567:505-521.
36. Hashino E, Shero M, Salvi RJ. Lysosomal targeting and accumulation of aminoglycoside antibiotics in sensory hair cells. Brain Res 1997;777:75-85.=65
37. Schacht J. Antioxidant therapy attenuates aminoglycoside-induced hearing loss. Ann.N.Y.Acad.Sci. 1999; 884:125-130.
38. Lesniak W, Pecoraro VL, Schacht J. Ternary complexes of gentamicin with iron and lipid catalyze formation of reactive oxygen species. Chem.Res.Toxicol. 2005; 18:357-364.
39. Priuska EM, Schacht J. Formation of free radicals by gentamicin and iron and evidence for an iron/gentamicin complex. Biochem.Pharmacol. 1995; 50:1749-1752.
40. Sha SH, Schacht J. Formation of reactive oxygen species following bioactivation of gentamicin. Free Radic.Biol.Med. 1999; 26:341-347.
41. Chandrasekhar SS, Tsai Do BS, Schwartz SR, Bontempo LJ, Faucett EA, Finestone SA, et al. Clinical Practice Guideline: Sudden Hearing Loss (Update). Otolaryngol Head Neck Surg 2019; 161(1_suppl):S1-S45. doi: 10.1177/0194599819859885. PMID: 31369359.
42. Kuhn M, Heman-Ackah SE, Shaikh JA, Roehm PC. Sudden Sensorineural Hearing Loss: A Reviewof Diagnosis, Treatment, and Prognosis. Trends Amplif 2011; 15:91-105.
43. Gombert E, George M, Maire R, Guilcher P. Surdité brusque: diagnostic et prise en charge en 2021 [Sudden sensorineural hearing loss: Diagnosis and management in 2021]. Rev Med Suisse. 2021; 6; 17(753):1694-1700. French. PMID: 34614310
44. Pai MP, Nafziger AN, Bertino JS Jr. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother. 2011; 55(9):4006-11. doi: 10.1128/AAC.00174-11.
45. Emmett SD, Schmitz J, Karna SL, Khatry SK, Wu L, LeClerq SC, et al. Early childhood undernutrition increases risk of hearing loss in young adulthood in rural Nepal. Am J Clin Nutr. 2018; 107(2):268-277. doi: 10.1093/ajcn/nqx022
46. Gonzalez LS 3rd, Spencer JP. Aminoglycosides: a practical review. Am Fam Physician. 1998 15; 58(8):1811-20. PMID: 9835856.
47. Elola A, Hien FM, Ouattara M, FataoFataho B, Kouassi B. Drépanocytose majeure et hypoacousie: à propos de 112 cas relevés à Yopougon, Côte d'Ivoire [Major sickle cell anaemia and hypoacusia: about 112 cases in Yopougon, Côte d'Ivoire]. Bull Soc Pathol Exot. 2009; 102(3):173-4. French. PMID: 19739413
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Mireille Avilaw Mpwate, Gauthier K. Mesia, Eddy Mampuya Mbambu, Gabriel Mabuaka Lema, Dominique Mayuku Mupepe, Luc Losenga Lukasu, Marc Mokanisa Bonsukie, Innocent Murhula Kashongwe, Zacharie Munogolo Kashongwe, Jean Marie Ntumba Kayembe, Richard Nzanza Matanda
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
